GOLD 2025 Report: Ensifentrine, a New Treatment in COPD

Author(s):

M. Bradley Drummond, MD, MHS,MeiLan K. Han, MD, MS

Panelists discuss how ensifentrine is a nebulized inhaled therapy, a small molecule inhibitor of PDE3 and PDE4, and is compelling because there are very few adverse effects. There are also compelling results from studies that show bronchial dilatation and exacerbation reduction.

EP: 1.Overview and Diagnosis of COPD

EP: 2.Risk Factors for COPD

EP: 3.Mortality and Comorbidities with COPD

EP: 4.Health and Economic Burden of COPD

EP: 5.Treatment of COPD Based on Symptoms

EP: 6.GOLD 2025 Report: Prebronchodilator Spirometry and Diagnosis of COPD

EP: 7.GOLD 2025 Report: Lung Microbiome and Chest CT Imaging in COPD

EP: 8.GOLD 2025 Report: Addressing Heart Disease in COPD

EP: 9.Blood Eosinophil Counts in COPD

Now Viewing

EP: 10.GOLD 2025 Report: Ensifentrine, a New Treatment in COPD

Video content above is prompted by the following:

The most impactful changes to the 2025 GOLD Report pertain to chronic obstructive pulmonary disease (COPD) management, specifically the addition of 2 new treatment options, ensifentrine and dupilumab, that were approved for use by the FDA in June 2024 and September 2024, respectively.
- What is ensifentrine (first-in-class PDE3 and PDE4 inhibitor), and how do its effects translate for the management of stable COPD?